SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 62.07 |
Enterprise Value ($M) | 50.51 |
Book Value ($M) | 8.91 |
Book Value / Share | 0.34 |
Price / Book | 6.97 |
NCAV ($M) | 8.29 |
NCAV / Share | 0.31 |
Price / NCAV | 7.49 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -2.21 |
Return on Assets (ROA) | -1.15 |
Return on Equity (ROE) | -1.70 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.99 |
Current Ratio | 2.99 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 13.74 |
Assets | 14.37 |
Liabilities | 5.46 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
41,605 | 141,627 | 29.38 | |
55,066 | 319,141 | 17.25 | |
31,014 | 166,711 | 18.60 | |
75,943 | 345,900 | 21.96 | |
(click for more detail) |
Similar Companies | |
---|---|
FHTX – Foghorn Therapeutics Inc. | FOLD – Amicus Therapeutics, Inc. |
FULC – Fulcrum Therapeutics, Inc. | GHRS – GH Research PLC |
HCWB – HCW Biologics Inc. |
Financial data and stock pages provided by
Fintel.io